Navigation Links
Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials

hospitalized heart failure patients,"(1) said Cesare Orlandi, M.D., vice president of Clinical Development at Otsuka Pharmaceutical Development & Commercialization, Inc.

Safety Data

Common adverse events associated with tolvaptan were dry mouth and thirst, which are consistent with the pharmacologic effects of the drug.(1,2) In the EVEREST trial, adverse events resulting in study drug discontinuation occurred in 6.5 percent of tolvaptan patients and 5.5 percent of placebo patients. Among these, only thirst occurred significantly more frequently with tolvaptan (n equal to 7) vs. placebo (n equal to 0); (p equal to 0.02). Dry mouth resulted in discontinuation in 4 tolvaptan patients vs. 0 placebo patients (p equal to 0.12).

Hypernatremia occurred in 1.7 percent of tolvaptan patients, compared to 0.5 percent of placebo patients. The incidence of kidney failure and low blood pressure were comparable in the two groups. Tolvaptan-treated patients showed no differences from placebo-treated patients with regards to heart rate and blood pressure. In addition, tolvaptan demonstrated no deleterious effects on renal function relative to placebo in these patients.(2)

About EVEREST

EVEREST is a landmark, prospective, international, multicenter, randomized, double-blind, placebo-controlled trial conducted at 432 sites in North America, South America and Europe between 2003 and 2006. EVEREST investigators randomized patients with worsening congestive heart failure and who had a left ventricular ejection fraction (LVEF) of 40 percent or less within 48 hours of their hospitalization to receive either 30 milligrams (mg) tolvaptan once-daily or a placebo until the end of the long-term outcome trial. Additionally, treating physicians could choose conventional therapies for their patients, including diuretics, digoxin, ACE inhibitors, angiotensin II receptor blockers, aldosterone blockers, beta-blockers, nitrates, nesiritide and/or hydralazine.(1)<
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease
Post Your Comments:
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
(Date:6/18/2013)...  Actavis, Inc. (NYSE: ACT ) today announced ... Securities and Exchange Commission (SEC) a registration statement on Form ... Chilcott plc (NASDAQ: WCRX ), which included ... (the "Form S-4"). As previously announced on ... entered into a definitive agreement pursuant to which Actavis will ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
... Ga., Dec. 23, 2010 MiMedx Group, ... integrated developer, manufacturer and marketer of patent protected biomaterial-based ... the Class III certification for a European product using ... certification for "post surgical adhesion inhibiting barriers" is in ...
... Pa., Dec. 23, 2010 Cephalon, Inc. (Nasdaq: ... appointed J. Kevin Buchi as Chief Executive Officer and a ... role of company Chairman in the future. William P. Egan ... "Kevin is an experienced pharmaceutical executive who has been ...
Cached Medicine Technology:MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 2MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 3MiMedx Receives Additional CE Certification for Its HydroFix™ Technology 4Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 2Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 3Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors 4
(Date:6/19/2013)... Pharmaceutical history is replete with ... with little or no understanding why they work, ... involved emerging years later. When Edward Tobinick ... rapid recovery of cognitive functions after perispinally administering ... known about the role inflammatory processes play in ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Middle ... throughout 2013 across all industries as cash rich buyers ... the differences across industries, all M&A transactions have a ... due diligence to verify the history and quality of ... considered. , But when due diligence involves a ...
(Date:6/19/2013)... Over the past five years, revenue ... has been growing at an annualized rate of 9.5% ... have supported the development of the industry including: substantial ... relatively higher drug prices in hospitals; and people's increased ... the development of chain drug retailing enterprises has also ...
(Date:6/18/2013)... Angeles, CA (PRWEB) June 19, 2013 ... of bariatric surgery, are holding complimentary weight loss seminars ... the detailed program can be accessed at their official ... minimizes surgery and recovery time. Their highly skilled panel ... to bariatric surgery. , A senior executive working ...
(Date:6/18/2013)... 18, 2013 Exposed Skin Care has finally ... acne suffers of all ages finally achieve the clear, beautiful ... products, this new acne clearing system combines the power of ... new acne from forming. , After a quick ... products are some of the most effective available on the ...
Breaking Medicine News(10 mins):Health News:Perispinally Administered Enbrel Facilitates Rapid Recovery of Cognitive Function in Patients with Alzheimer's 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 2Health News:Newport Board Group, a National Business Advisory Firm of CEOs Cautions Buyers on 5 Questions to Ask Before Acquiring a Technology-Based Middle Market Company 3Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3
... VANCOUVER, APRIL 1, 2009 New research funded by ... and learning difficulties for some childhood cancer survivors, especially ... in the journal Cancer , raises critical questions ... , "These are very significant findings," says Barbara Kaminsky, ...
... nurses, doctors and other front line cancer-care providers significantly ... with other healthcare workers, and with their own family, ... and Regenstrief Institute researchers published in the March issue ... , "The healthcare field is becoming more aware of ...
... new study, a therapeutic agent called sorafenib dramatically improved the ... approved in several countries for treatment of kidney and liver ... patients suffering from advanced portal hypertension, the authors suggest. Their ... a journal published by John Wiley & Sons on behalf ...
... out to adopt a child, the world pays attention. ... Malawi -- a small impoverished African nation. In ... to over a million, help is needed in many forms. ... with a mother and siblings, and the essentials of childhood ...
... physician groups clearly understand how to effectively analyze ... to be more innovative and establish more effective ... consultants The Practice Pros and Mediplay, Inc. have ... with assessing their marketing effectiveness. To take ...
... marketer of PurinaCare (R) Pet Health Insurance ( ... ( www.kgbtexas.com ) as its PR agency of ... June 2008, and is currently authorized to market pet health ... will help create and implement a strategic public relations and ...
Cached Medicine News:Health News:New research shows lower educational outcomes for survivors of childhood cancer 2Health News:Compassion fatigue: Impact on healthcare providers of caring for the terminally ill 2Health News:Compassion fatigue: Impact on healthcare providers of caring for the terminally ill 3Health News:Medication may improve portal hypertension 2Health News:In Malawi, Adoption is Not Enough 2Health News:Hey Doc, What's Your Marketing Strategy? 2Health News:Hey Doc, What's Your Marketing Strategy? 3Health News:KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance 2Health News:KGBTexas Named Public Relations Agency of Record for PurinaCare(R) Pet Health Insurance 3
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... 4F, 5F, and 6F ... is ideal for coronary ... state-of-the-art technology and proprietary ... better responsiveness, optimal torque, ...
Medicine Products: